Sinovac COVID-19 Vaccine

CoronaVac, SinoVac Biotech Co.

Administration

Vaccine

  • Sinovac COVID-19 vaccine, Coronavac

Authorized for Use in

  • China. WHO EUL. Meets US Entry requirements.

Age

  • > 18 yrs

Type

  • Inactivated

Primary Dosing

  • 2 doses 14 or 28 days apart

Booster Dosing

  • Booster at 6 months after Dose 2 implemented in several countries. WHO recommends 3rd dose for persons over 60 and 1-3 months after dose 2 in immune compromised but labels as 3rd dose in a primary series.
  • Three doses of mRNA vaccine is the only current effective strategy against the Omicron variant

Interchangeability

  • WHO allows another kind of vaccine to be used for Dose 3 of Sinovac.
  • CDC recommends that persons aged ≥ 18 years (including moderately or severely immunocompromised persons who received an additional primary dose) who were fully vaccinated with a WHO EUL vaccine not authorized/approved by US FDA or with a heterologous series composed of any FDA-authorized/approved or WHO EUL authorized vaccine are eligible to receive a single booster dose of the Pfizer vaccine (0.3 mL; 30 µg) at least 6 months after completion of their primary series under the existing age guidelines as for Moderna and Pfizer vaccines. Practically, either mRNA vaccine may be used for a booster in this situation.

Storage

  • 2-8°C (36-46°F)

Efficacy

Overall against symptomatic disease

  • 67% (WHO EUL analysis).  Trials in Chile, China, Brazil, Turkey with highly variable results.

Real world against hospitalization

  • Chile: 87.5% against hospitalization;

Age > 65 years

  • Little data for age > 60 yrs

Pediatric

  • Not approved

Against severe disease / death

  • 80% in large Chilean trial

Against asymptomatic infection / transmission

  • No data

Duration of efficacy after final dose

  • No data

Toxicities

Contraindications

  • No data

Precautions

  • No data

Not contraindications

  • No data

Adverse effects

  • No data

Special Needs Populations

Pregnancy

  • No data

Immunocompromised / HIV

  • WHO recommends 3 dose primary series with dose 3 at 1-3 months following dose 2. WHO allows another kind of vaccine to be used for Dose 3.